Our R&D Portfolio

GeneICE – Bcl-2 is a novel therapeutic based on the Company’s proprietary GeneICE (Gene Inactivation by chromatin engineering) platform, which has attracted c. €3 million in Eurostars grants to fund its development.

The therapeutic acts to target and switch “OFF” the gene that expresses Bcl-2, a protein that is implicated in about half of all carcinomas. Bcl-2 inhibits the critical process of apoptosis (programmed cell death), which prevents cancer development. Thus, because of its function in anti-apoptosis, the Bcl-2 gene has become a major target in the development of new, superior anti-cancer therapies.